Clinical

New research highlights the factors that increase the likelihood that essential thrombocytopenia (ET), polycythemia vera (PV), and prefibrotic primary myelofibrosis (PrePMF) will evolve into overt myelofibrosis (MF).

Advances in multi-omics have led to large scale studies that can provide a better prediction method for adequate therapy choices in patients with chronic lymphocytic leukemia (CLL).

A recent study found significant variation in the use of recommended laboratory tests ahead of immunomodulatory treatment in patients with chronic inflammatory skin diseases, with less than 60% of patients in the US receiving recommended pretreatment testing.

A review explores the evidence supporting the use of circulating tumor DNA (ctDNA) liquid biopsies to help direct the evaluation and management of EGFR-mutated non–small cell lung cancer (NSCLC), including for assessing resistance to certain treatment options.

Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.

A blood-based test using cell-free DNA had high sensitivity for colorectal cancer, high specificity for advanced neoplasia, and some sensitivity for advanced precancerous lesions.

Patients experienced clinically meaningful improvements in health-related quality of life (HRQoL) factors after 6 months of guselkumab, according to one study.

A retrospective analysis of Canadian cases finds clinicians turn to a variety of therapies for chronic graft-vs-host disease (GVHD) if corticosteroids fail.

Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.

Posters suggest deuruxolitinib, a medication targeting specific cellular pathways, effectively promotes hair regrowth in patients with moderate to severe alopecia areata (AA) and results in minimal adverse events.

Patients with stage IV colorectal cancer (CRC) had lower overall and disease-free survival if they had a pelvic exenteration (PE) or cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Results come amid the FDA's review of chimeric antigen receptor (CAR) T-cell therapy.

Results demonstrated a nonlinear relationship between admission heart rate (AHR) and in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and respiratory failure (RF).

This new analysis provides an optimistic outlook on the future of chronic lymphocytic leukemia (CLL) treatment and discoveries into the background behind CLL transformation into Richter syndrome.

Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024.

Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.

Telehealth, which increased 63-fold from 2019 to 2020, has potential for managing and delivering care to patients with rheumatic diseases.

Compared with matched controls, patients with myeloproliferative neoplasms (MPNs) had a higher risk of developing thrombosis, hemorrhage, and leukemic transformation, according to a longitudinal cohort study.

Research found that maternal loss of a partner or older child, as well as the loss of a close relative due to unnatural causes in the year before or during pregnancy, were linked to a heightened risk of heart failure in offspring.

Amy S. Paller, MD, chair of the department of dermatology at Feinberg School of Medicine at Northwestern University, discussed using systemic therapies to treat children with atopic dermatitis (AD).

Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.

Robert Gabbay, MD, PhD, discusses the early intervention at the asymptomatic stages of type 1 diabetes characterized by autoimmune antibodies and gradual blood sugar elevations.

A medical expert discusses treatment decision-making and modalities for ovarian cancer, including palliative care and hospice.

Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.

The panel provides an overview of the various Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment phases, highlighting the important discussion around inpatient versus outpatient care.

The panel discusses optimal strategies for screening and detecting Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients across different treatment stages.

Novo Nordisk is working with authorities in several countries to tackle counterfeit versions of popular diabetes drug semaglutide (Ozempic); Amylyx’s controversial amyotrophic lateral sclerosis (ALS) drug failed to help patients in a large follow-up study; disruptions from the Change Healthcare cyberattack are costing health providers as much as $1 billion a day.

Increased interest in screening for the genetic risk of type 1 diabetes (T1D) has been driven by factors including the introduction of immune interventions.

A considerable number of patients with atopic dermatitis (AD) and limited health literacy, especially older individuals, experienced impaired health-related quality of life.